To help Indian researchers access a portfolio of excellent services from BioOutsource and Cellca
Glasgow, UK – June 29, 2016: Sartorius Stedim Biotech (SSB), an international leading supplier for the biopharmaceutical industry, is pleased to announce that its subsidiary BioOutsource has appointed Ravin Mehta as Technical Sales Specialist to enable customers to have access to Cellca and BioOutsource’s early stage development services for biosimilar drug candidates.
Prior to joining BioOutsource, Ravin spent over 10 years in biosimilar product development, where he gained experience in cGMP manufacturing as an upstream bioprocess scientist with two of India’s major biopharmaceutical companies. He also attained skills in management by supporting biologics development services for WuXi AppTec, one of Asia’s largest biopharma firms. His technical expertise is underpinned by a degree in biotechnology from Saurashtra University and an MBA in marketing from The Maharaja Sayajirao University of Baroda.
Ravin Mehta, Technical Sales Specialist at BioOutsource commented: “I am excited to be utilising my knowledge and experience of the Indian biosimilar industry to bring Cellca and BioOutsource’s leading portfolio to biopharma firms here.”
Mitch Scanlan, Director of Sales and Marketing at BioOutsource concluded: “India is a growing market for vaccine and biosimilar production and we are expanding our technical team to meet the need for accessing our unique services here. We’re delighted to have recruited a biosimilar expert like Ravin because he can explain how our analytical expertise can help scientists enter clinical programmes more rapidly and provide a competitive edge with their biologics’ development.”
For information about BioOutsource and Cellca in India, scientists should click these links:
www.biooutsource.com/biosimilars/
www.biooutsource.com/cell-line-and-upstream-process-development/
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros.
A profile of Sartorius Stedim BioOutsource Ltd.
Now part of Sartorius Stedim Biotech Group, BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of biologics, vaccines & biosimilars throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry’s increasingly preferred testing partner. We understand the importance of our service to support our client’s critical testing requirements and as a result, continually strive to provide a world class service globally.
A profile of Sartorius Stedim Cellca GmbH
Cellca, founded in 2005 and part of the Sartorius Stedim Biotech Group, is a leading provider of cell line and upstream process development services for large-scale protein production of biopharmaceuticals in mammalian cells. Based on our in-depth expertise, know-how, and intellectual property, we have established the unique CHO Expression Platform technology, which is designed to deliver high yielding, stable CHO cell lines and robust, scalable fed-batch processes for the pharma and biotech industries. Our customers and partners benefit from a reduction of their cost of goods, the reduction of development risks, and a faster time-to-clinic.
